Archived Press Releases

Nov 29, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 05, 2024

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results

Nov 01, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 02, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Sep 03, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 08, 2024

Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results

Aug 02, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 01, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jun 28, 2024

Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors